Search results for "active metabolite"

showing 10 items of 22 documents

Induction of Drug Transporters Alters Disposition of Risperidone - A Study in Mice

2010

Pharmacokinetic interactions, e.g. modulation of drug transporters like P-glycoprotein at the blood-brain barrier, can be a reason for treatment non-response. This study focuses on the influence of induction of drug transporters on the disposition of the antipsychotic drugs risperidone and 9-hydroxyrisperidone. Brain and serum concentrations of risperidone and its active metabolite 9-hydroxyrisperidone, which are known P-glycoprotein substrates, were measured after drug transporter induction with rifampicin, dexamethasone or 5-pregnene-3beta-ol-20-on-16alpha-carbonitrile using high performance liquid chromatography. Disposition of risperidone and 9-hydroxyrisperidone was dramatically decrea…

Drugmedia_common.quotation_subjectmedicine.medical_treatmentlcsh:RS1-441Pharmaceutical ScienceP-glycoproteinPharmacologyArticlelcsh:Pharmacy and materia medicaPharmacokineticsMedicineAntipsychoticDexamethasoneActive metaboliteP-glycoproteinmedia_commonrisperidoneRisperidonebiologybusiness.industryTransporterdrug transporterantipsychoticsdispositionbiology.protein9-hydroxyrisperidonebusinessmedicine.drugPharmaceutics
researchProduct

Reduction of clozapine-induced hypersalivation by pirenzepine is safe.

2004

Introduction Hypersalivation is known as a frequent, disturbing, and socially stigmatizing side effect of therapy with the atypical antipsychotic clozapine. It has been shown that the addition of the anticholinergic pirenzepine is able to reduce clozapine-induced hypersalivation, probably by blocking M4-receptors. Nevertheless, a pharmacokinetic interaction between both compounds cannot be excluded. Methods In this pilot study, 29 schizophrenic patients (ICD-10; 51.7 % female; age: 36.7 +/- 8.7 years [mean +/- SD]) were included. Serum concentrations of clozapine and its pharmacologically active metabolite N-desmethylclozapine were determined under steady-state conditions by automated HPLC …

HypersalivationAdultMalemedicine.medical_specialtySide effectmedicine.drug_classAtypical antipsychoticPilot ProjectsMuscarinic AntagonistsPharmacologyInternal medicinemedicineAnticholinergicHumansPharmacology (medical)Drug InteractionsClozapineClozapineActive metaboliteChromatography High Pressure LiquidCross-Over StudiesDose-Response Relationship DrugChemistryGeneral MedicinePirenzepineSialorrheaMiddle AgedPirenzepinePsychiatry and Mental healthDose–response relationshipEndocrinologySchizophreniaFemaleSpectrophotometry Ultravioletmedicine.symptommedicine.drugAntipsychotic AgentsPharmacopsychiatry
researchProduct

Substantial Fat Loss in Physique Competitors Is Characterized by Increased Levels of Bile Acids, Very-Long Chain Fatty Acids, and Oxylipins.

2022

Funder: Finnish Foundation for Cardiovascular Research

LC-MS metabolomeexercisekuntoliikuntalaihdutusvisceral fat massliikuntaweight lossbioactive metabolitesaineenvaihduntafyysinen aktiivisuusArticlepainonhallinta
researchProduct

Controlled transdermal iontophoresis for poly-pharmacotherapy: Simultaneous delivery of granisetron, metoclopramide and dexamethasone sodium phosphat…

2015

Iontophoresis has been used to deliver small molecules, peptides and proteins into and across the skin. In principle, it provides a controlled, non-invasive method for poly-pharmacotherapy since it is possible to formulate and to deliver multiple therapeutic agents simultaneously from the anodal and cathodal compartments. The objective of this proof-of-principle study was to investigate the simultaneous anodal iontophoretic delivery of granisetron (GST) and metoclopramide (MCL) and cathodal iontophoresis of dexamethasone sodium phosphate (DEX-P). In addition to validating the hypothesis, these are medications that are routinely used in combination to treat chemotherapy-induced emesis. Two p…

MaleMetoclopramideSwinePharmaceutical Science02 engineering and technologyPharmacologyGranisetronAdministration Cutaneous030226 pharmacology & pharmacyDexamethasoneGranisetron03 medical and health sciences0302 clinical medicineDexamethasone Sodium PhosphatePharmacokineticsIn vivomedicineAnimalsRats WistarDexamethasoneActive metaboliteTransdermalSkinIontophoresisChemistryHydrolysisIontophoresis021001 nanoscience & nanotechnologyRatsPolypharmacy0210 nano-technologymedicine.drugEuropean journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
researchProduct

INULIN BASED HYDROGEL FOR ORAL DELIVERY OF FLUTAMIDE: PREPARATION, CHARACTERIZATION AND IN VIVO RELEASE STUDIES

2012

The ability of a hydrogel obtained by crosslinking INUDV and PEGBa to facilitate sustained release of flutamide is examined. The hydrogel is prepared in pH = 7.4 PBS and no toxic solvents or catalysts are used. It is recovered in microparticulate form and its size distribution is determined. Mucoadhesive properties are evaluated in vitro by reproducing gastrointestinal conditions. Flutamide is loaded into the hydrogel using a post-fabrication encapsulation procedure that allows a drug loading comparable to that of market tablets. Drug-loaded microparticles are orally administered to cross-bred dogs and the in vivo study demonstrates their ability to prolong the half-life of the principal ac…

MalePolymers and PlasticsInulinAdministration OralBiological AvailabilityBioengineeringPharmacologyFlutamideBiomaterialschemistry.chemical_compoundDogsDrug Delivery SystemsIn vivoMaterials ChemistryDistribution (pharmacology)AnimalsHypoglycemic AgentsInsulinActive metabolitetechnology industry and agricultureAndrogen AntagonistsHydrogelsIn vitroFlutamideBioavailabilitychemistrySelf-healing hydrogelsBiotechnologyHalf-Life
researchProduct

Synergistic platelet antiaggregatory effects of the adenylate cyclase activator iloprost and the guanylate cyclase activating agent SIN-1 in vivo

1993

The aim of our study was to evaluate the platelet antiaggregatory and hemodynamic effects of the stable prostacyclin analog iloprost and the NO-donor SIN-1, an active metabolite of molsidomine. The number of circulating platelets was determined in anesthetized male Wistar rats as a measure of in vivo platelet aggregation. Platelet count decreased from 648 +/- 25 to 476 +/- 15 x 10(3) platelets/microliter and from 578 +/- 36 to 411 +/- 40 (mean +/- SEM) in response to two repetitive injections of collagen (70 micrograms/kg body weight). Treatment with SIN-1 bolus injections (0.3 or 1 mg/kg bw) and/or continuous i.v. infusion of iloprost (0.2 or 0.4 micrograms/kg bw/min) was initiated 15 min …

Malemedicine.medical_specialtyMolsidominePlatelet AggregationPlatelet aggregationBlood PressureProstacyclinNitric Oxidechemistry.chemical_compoundIn vivoInternal medicinemedicineAnimalsPlateletIloprostRats WistarAntihypertensive AgentsActive metaboliteChemistryDrug SynergismHematologyRatsEnzyme ActivationEndocrinologyGuanylate CyclaseMolsidomineAdenylyl Cyclase InhibitorsPlatelet Aggregation InhibitorsSignal TransductionIloprostmedicine.drugGuanylate cyclaseThrombosis Research
researchProduct

Antifungal Activity of Bioactive Metabolites Produced by Trichoderma asperellum and Trichoderma atroviride in Liquid Medium

2020

Trichoderma spp. are known as biocontrol agents of fungal plant pathogens and have been recognized as a potential source of bioactive metabolites. The production of antimicrobial substances from strains T. atroviride (TS) and T. asperellum (IMI 393899) was investigated. The bioactivity of 10- and 30-day culture filtrate extracted with ethyl acetate was assessed against a set of pathogenic fungi and oomycetes. The 30-day extracts of both strains had significant cytotoxic effects against the tested pathogens, with values of minimum fungicidal concentration (MFC) ranging between 0.19 and 6.25 mg/mL. Dual culture assay (direct contact and nondirect contact) and the percentage inhibition of radi…

Microbiology (medical)Ethyl acetateBiological pest controlbiological controlPlant ScienceLiquid mediumplant pathogensTrichoderma atroviride03 medical and health scienceschemistry.chemical_compoundFood science<i>Trichoderma asperellum</i>lcsh:QH301-705.5Ecology Evolution Behavior and Systematics030304 developmental biology0303 health sciencesbiology030306 microbiologyChemistryBiological activity<i>Trichoderma atroviride</i>biology.organism_classificationAntimicrobialTrichoderma asperellumlcsh:Biology (General)Trichodermabioactive metabolitesJournal of Fungi
researchProduct

Inhibition of Mycotoxigenic Fungi in Different Vegetable Matrices by Extracts of Trichoderma Species

2021

Post-harvest fungal diseases of plant products are a serious concern leading to economic losses and health risks. Moreover, the use of synthetic chemical fungicides to prevent these diseases is limited due to toxic residues. This study aimed at determining the effective dose of extracts of Trichoderma&nbsp

Microbiology (medical)Ochratoxin AAflatoxinTrichoderma asperellumQH301-705.5Biological pest controlbiological controlPlant ScienceBiologyArticlechemistry.chemical_compoundmycotoxinsFood scienceTrichoderma atrovirideBiology (General)MycotoxinEcology Evolution Behavior and Systematicsfood and beveragesContaminationTrichoderma asperellumEffective dose (pharmacology)<i>Trichoderma</i> <i>atroviride</i>FungicideTrichoderma atroviridechemistry<i>Trichoderma</i> <i>asperellum</i>bioactive metabolitesTrichoderma speciesJournal of Fungi
researchProduct

Effects of EPHX1 and CYP3A4 polymorphisms on carbamazepine metabolism in epileptic patients

2014

Antonietta Caruso, Chiara Bellia, Alessia Pivetti, Luisa Agnello, Federica Bazza, Concetta Scazzone, Giulia Bivona, Bruna Lo Sasso, Marcello CiaccioDepartment of Biopathology and Medical and Forensic Biotechnologies, University of Palermo, Palermo, ItalyBackground: The aim of this study was to investigate the effect of two genetic polymorphisms in the coding regions (exon 3 and exon 4) of the EPHX1 gene, ie, 337T&amp;gt;C and 416A&amp;gt;G, respectively, on the metabolism of carbamazepine (CBZ) 10,11-epoxide (the active metabolite of CBZ) by evaluating the variation in serum CBZ 10,11-epoxide levels 4 hours after administration of the drug. Moreover, we reported the genotype frequencies of …

PharmacologyCYP3A4business.industryCarbamazepineEPHX1Pharmacologydrug metabolismGenotype frequency11-epoxidePharmacogenomics and Personalized MedicineIn vivoGenotypemedicineMolecular MedicineCBZ 10EPHX1 genebusinessActive metaboliteDrug metabolismCYP3A4*22medicine.drugOriginal ResearchPharmacogenomics and Personalized Medicine
researchProduct

Current Evidence, Challenges, and Opportunities of Physiologically Based Pharmacokinetic Models of Atorvastatin for Decision Making

2021

Atorvastatin (ATS) is the gold-standard treatment worldwide for the management of hypercholesterolemia and prevention of cardiovascular diseases associated with dyslipidemia. Physiologically based pharmacokinetic (PBPK) models have been positioned as a valuable tool for the characterization of complex pharmacokinetic (PK) processes and its extrapolation in special sub-groups of the population, leading to regulatory recognition. Several PBPK models of ATS have been published in the recent years, addressing different aspects of the PK properties of ATS. Therefore, the aims of this review are (i) to summarize the physicochemical and pharmacokinetic characteristics involved in the time-course o…

Physiologically based pharmacokinetic modellingModel predictionAtorvastatinPopulationPharmaceutical ScienceReviewTarget populationComputational biologyP-glycoprotein030226 pharmacology & pharmacy03 medical and health sciencesPharmacy and materia medica0302 clinical medicinePharmacokineticsmedicineopen acid formeducationeducation.field_of_studybusiness.industrysolubilityatorvastatinactive metabolitesRS1-441lactonizationDose optimizationMetabolic enzymes030220 oncology & carcinogenesisbusinessmedicine.drugPharmaceutics
researchProduct